I will make Social Security and Medicare more efficient by cracking down on waste, fraud, and abuse, and I will let Medicare negotiate drug prices.

Instead, I advocate for making these programs more efficient by cracking down on waste, fraud, and abuse, and letting Medicare negotiate the cost of drug prices.

Scholten commits to improving Social Security and Medicare efficiency by combating waste, fraud, and abuse and enabling Medicare drug-price negotiation.

Social Security and Medicare - Hillary Scholten for Congress
campaign · campaign_site · model gpt-5.4-mini

Congresswoman Hillary J. Scholten is honored to serve the people of Michigan’s Third Congressional District... Congresswoman Scholten now serves as the first woman and mother ever to represent Michigan’s Third District in Congress.

Establishes the relevant federal office for judging the promise: Scholten serves as U.S. representative for Michigan's 3rd District. Her official site also states she is currently serving her second term.

unresolved unknown

About | Representative Hillary Scholten
secondary · model gpt-5.5 · confidence 92%

SEC. 11001. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE SOURCE DRUGS... The Secretary shall establish a Drug Price Negotiation Program... negotiate and, if applicable, renegotiate maximum fair prices for such selected drugs... initial price applicability year... beginning with 2026.

The Inflation Reduction Act created Medicare's drug price negotiation program and required HHS to negotiate maximum fair prices for selected drugs beginning with 2026. This fulfills the policy substance of allowing Medicare negotiation, although the law was enacted before Scholten entered Congress.

delivered unknown

Public Law 117-169, Inflation Reduction Act of 2022
secondary · model gpt-5.5 · confidence 97%

For any selected drugs for which CMS and participating drug companies have agreed upon negotiated prices under the Medicare Drug Price Negotiation Program... the file also contains the single negotiated price... The below links contain the MFP explanations for the 10 drugs covered under Medicare Part D that were selected for the first cycle of negotiations; the MFPs will go into effect on January 1, 2026.

CMS records show Medicare drug-price negotiation moved from statutory authorization to implementation: CMS and drug companies agreed on maximum fair prices, with the first cycle effective January 1, 2026 and later cycles continuing.

delivered same_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.5 · confidence 98%

CMS announced on March 13, 2026 that the drug companies that manufacture all 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiation have chosen to participate in the Negotiation Program... The negotiations with participating drug companies will occur in 2026, and any negotiated prices will become effective beginning in 2028.

CMS shows the Medicare negotiation program is continuing and expanding to additional drugs, including Part B and Part D drugs selected for the 2028 initial price applicability year.

delivered same_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.5 · confidence 95%

CMS is crushing fraud, waste, and abuse to protect Americans... Total Medicare program integrity savings surged 59%, from $26.3 billion in FY 2024 to a record-shattering $41.9 billion in FY 2025. The FY 2025 Medicare Return on Investment (ROI) reached $22.3 to 1.

CMS reports major Medicare program-integrity savings and anti-fraud activity during Scholten's federal service. This supports the Medicare waste/fraud/abuse portion as a national administrative outcome, but it does not show Scholten personally enacted or advanced the action and does not address Social Security.

partial same_term

Crushing Fraud, Waste, & Abuse | CMS
secondary · model gpt-5.5 · confidence 86%

CMS is continuing its broader crackdown on fraud by imposing nationwide Medicare enrollment moratoria focused on high-risk providers, including home health agencies, hospices, and certain Durable Medical Equipment, Prosthetics, Orthotics, and Suppliers (DMEPOS) suppliers. The moratoria prohibit new enrollments for those provider types for a six-month window.

CMS documents concrete Medicare anti-fraud measures in 2026. This is relevant to cracking down on Medicare waste, fraud, and abuse, but it is an executive-branch CMS action rather than a Scholten legislative achievement.

partial same_term

Crushing Fraud, Waste, & Abuse | CMS
secondary · model gpt-5.5 · confidence 84%

Member Activity by Hillary J. Scholten... Sponsored Legislation [35]... Cosponsored Legislation (All) [603]... Subject - Policy Area... Health [115]... Status of Legislation... Became Law [10].

Congress.gov confirms Scholten has sponsored and cosponsored legislation during the 118th and 119th Congresses, including health-related measures. The available member-activity page does not, by itself, prove that she introduced or passed a specific Social Security/Medicare fraud bill or Medicare negotiation bill.

unresolved unknown

Hillary J. Scholten | Congress.gov | Library of Congress
secondary · model gpt-5.5 · confidence 72%

Public Law 117-169... Aug. 16, 2022 - [H.R. 5376]... PART 1--LOWERING PRICES THROUGH DRUG PRICE NEGOTIATION... SEC. 11001. PROVIDING FOR LOWER PRICES FOR CERTAIN HIGH-PRICED SINGLE SOURCE DRUGS.

The principal Medicare negotiation promise was already enacted in August 2022, before Scholten's congressional service began in January 2023. That makes the policy delivered nationally, but weakens attribution to Scholten as a member of Congress.

partial unknown

Public Law 117-169, Inflation Reduction Act of 2022
secondary · model gpt-5.5 · confidence 93%